South African tycoon Stephen Saad's Aspen pulls out of making the HIV prevention shot
Aspen has withdrawn from South Africa's plan to make Gilead's HIV prevention injection locally, with Stephen Saad citing the absence of purchase guarantees.
Stephen Saad
South African billionaire Stephen Saad is selling weight-loss drugs faster than anything he has seen
Aspen's normalised headline earnings rose 28% in constant currency on flat revenue, as Mounjaro took 53% of South Africa's weight-loss market.
South African billionaires Stephen Saad and Mike Teke are backing a $99 million township fibre push
The DNI consortium paid R1.6 billion for 34.8% of Frogfoot and Vox, a business that lost R256 million and has negative net asset value of R665m.
Stephen Saad's Aspen secures royalty-free rights to Merck's once-monthly HIV pill
Stephen Saad's Aspen Pharmacare is one of seven drugmakers licensed to make Merck's once-monthly HIV prevention pill in 129 countries.
Aspen, controlled by tycoon Stephen Saad, wins Canadian approval for generic Ozempic
Stephen Saad's Aspen Pharmacare has won Canadian approval for a generic Ozempic, but an ingredient supply failure will keep it off shelves for months.
Aspen Pharmacare's $1.6 billion APAC sale adds $33 million to Stephen Saad's net worth
Aspen Pharmacare shares surged 7% after completing its R27bn APAC sale, adding approximately R550 million ($33.5 million) to Stephen Saad's fortune in a single trading session.
Stephen Saad's Aspen Pharmacare predicts double-digit growth despite tough first half
Aspen Pharmacare reported a steep drop in first-half earnings due to one-off restructuring costs but expects double-digit profit growth by year-end.
Stephen Saad's Aspen Pharmacare is racing to get Generic Ozempic approved in Canada by September
Africa's largest drugmaker is gunning for a Canadian green light on its generic version of Ozempic's key ingredient before summer ends.
Aspen Pharmacare founder Stephen Saad eyes Canada as first proving ground for generic Ozempic rivals
Aspen founder Stephen Saad wants Canada to be the proving ground for generic semaglutide, as competitors race regulators and supply constraints.
South African pharma tycoon Stephen Saad’s Aspen to sell Asia-Pacific assets for $1.59 billion
Stephen Saad’s Aspen will sell most Asia-Pacific operations for $1.59 billion as the drugmaker trims debt and reshapes its global footprint.
South African tycoon Stephen Saad loses $19 million from Aspen stake
Stephen Saad’s Aspen Pharmacare stake loses $19 million as shares fall, highlighting mounting pressure on Africa’s largest drugmaker.
South African tycoon Stephen Saad’s Aspen stake loses $18 million
Stephen Saad’s Aspen stake drops $18 million as shares fall 5.45% in 16 days, deepening losses for South Africa’s largest drugmaker.
Aspen’s market slide wipes $20 million off Stephen Saad’s stake
Stephen Saad’s Aspen Pharmacare stake drops by $20 million as the company’s stock slips 6 percent on the Johannesburg Stock Exchange (JSE).
South African pharma tycoon Stephen Saad’s Aspen stake tops $340 million
Aspen Pharmacare shares edge higher, boosting CEO Stephen Saad’s holdings above $340 million despite the stock’s 37% year-to-date decline.
South Africa’s Stephen Saad expects $50 million sales from Aspen’s weight loss drug
South African pharma tycoon Stephen Saad says Aspen’s weight loss drug could reach $50 million in sales within two years.
South African tycoon Stephen Saad’s Aspen Pharmacare swings to $61.4 million loss in 2025
Aspen Pharmacare reports $61.34 million loss as revenue falls 3 percent, driven by restructuring and manufacturing challenges.